Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: placebo + fluoxetine Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)

NCT01672255
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
Interventions
Fluoxetine, Placebo control
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 4 Interventional Results available

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

NCT00288574
View directory record Official record
Conditions
Anorexia Nervosa, Eating Disorders
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 4 Interventional

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

NCT01185977
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Sep 26, 2026, 6:08 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

NCT05948553
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 26, 2026, 6:08 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

NCT05422612
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 26, 2026, 6:08 AM EDT
Withdrawn Phase 2 Interventional

RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke

NCT01963832
View directory record Official record
Conditions
Severe Stroke With Affected Arm Motor Function
Interventions
Fluoxetine, Placebo, eCMIT, Usual Care
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2015 · Synced Sep 26, 2026, 6:08 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD

NCT04131829
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Fluoxetine - immediate treatment, Fluoxetine - delayed treatment
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 26, 2026, 6:08 AM EDT
Withdrawn Early Phase 1 Interventional

Fluoxetine Prevention Trial

NCT01615055
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
Fluoxetine, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

NCT02929667
View directory record Official record
Conditions
Epilepsy, SUDEP
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Rup Kamal Sainju
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 3, 2020 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 4 Interventional

Substance Dependent Teens - Impact of Treating Depression Study 1 - 1

NCT00061113
View directory record Official record
Conditions
Alcohol-Related Disorders, Marijuana Abuse, Substance-Related Disorders
Interventions
Fluoxetine + outpatient cognitive behavioral therapy, fluoxetine, placebo + CBT
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
13 Years to 19 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 26, 2026, 6:08 AM EDT
Recruiting Phase 4 Interventional

Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma?

NCT06046859
View directory record Official record
Conditions
Musculoskeletal Injury
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 26, 2026, 6:08 AM EDT
Terminated Phase 2 Interventional Results available

Fluoxetine for Visual Recovery After Ischemic Stroke

NCT02737930
View directory record Official record
Conditions
Acute Stroke, Visual Field Loss
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Bogachan Sahin
Other
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hypoglycemia Associated Autonomic Failure in Type 1 DM

NCT00592670
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Not applicable Interventional Results available

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

NCT00965562
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Fluoxetine, Calcium, Placebo
Drug
Lead sponsor
Donaghue Medical Research Foundation
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Not applicable Interventional

Study of Fluoxetine in Adults With Autistic Disorder

NCT00027404
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 26, 2026, 6:08 AM EDT
Withdrawn Early Phase 1 Interventional

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

NCT04570449
View directory record Official record
Conditions
Covid19
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

Poststroke Depression in Hemorrhagic Stroke

NCT03826875
View directory record Official record
Conditions
Stroke Hemorrhagic, Depression
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2020 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 4 Interventional Results available

Fluoxetine in Pediatric Body Dysmorphic Disorder

NCT00245635
View directory record Official record
Conditions
Body Dysmorphic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Up to 16 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
The Bronx, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 26, 2026, 6:08 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 26, 2026, 6:08 AM EDT